EGFR and non-small cell lung carcinoma: To ascertain the potential benefits of combination therapy as a neoadjuvant treatment for patients with stage III-N2 EGFR-mutant NSCLC, it may be necessary to conduct a long-term follow-up study to evaluate its impact on disease-free survival and overall survival.